46 related articles for article (PubMed ID: 28665392)
21. Glibenclamide for acute brain edema. Is the good news coming?
Welling LC; Welling MS; Teixeira MJ; Figueiredo EG
World Neurosurg; 2015 Mar; 83(3):281-2. PubMed ID: 25598419
[No Abstract] [Full Text] [Related]
22. [Glibenclamide as a promising agent for prevention and treatment of cerebral edema].
Tsarenko SV; Dzyadz'ko AM; Rybalko SS
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):88-93. PubMed ID: 28665392
[TBL] [Abstract][Full Text] [Related]
23. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date.
King ZA; Sheth KN; Kimberly WT; Simard JM
Drug Des Devel Ther; 2018; 12():2539-2552. PubMed ID: 30147301
[TBL] [Abstract][Full Text] [Related]
24. Glibenclamide in cerebral ischemia and stroke.
Simard JM; Sheth KN; Kimberly WT; Stern BJ; del Zoppo GJ; Jacobson S; Gerzanich V
Neurocrit Care; 2014 Apr; 20(2):319-33. PubMed ID: 24132564
[TBL] [Abstract][Full Text] [Related]
25. Potential of glyburide to reduce intracerebral edema in brain metastases.
Boggs DH; Simard JM; Steven A; Mehta MP
Expert Rev Neurother; 2014 Apr; 14(4):379-88. PubMed ID: 24552576
[TBL] [Abstract][Full Text] [Related]
26. Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans.
Khanna A; Walcott BP; Kahle KT; Simard JM
Neurosurg Focus; 2014 Jan; 36(1):E11. PubMed ID: 24380477
[TBL] [Abstract][Full Text] [Related]
27. Role of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence.
Jha RM; Bell J; Citerio G; Hemphill JC; Kimberly WT; Narayan RK; Sahuquillo J; Sheth KN; Simard JM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936452
[TBL] [Abstract][Full Text] [Related]
28. BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema.
Pergakis M; Badjatia N; Chaturvedi S; Cronin CA; Kimberly WT; Sheth KN; Simard JM
Expert Opin Investig Drugs; 2019 Dec; 28(12):1031-1040. PubMed ID: 31623469
[No Abstract] [Full Text] [Related]
29. Glibenclamide for Brain Contusions: Contextualizing a Promising Clinical Trial Design that Leverages an Imaging-Based TBI Endotype.
Jha RM; Simard JM
Neurotherapeutics; 2023 Oct; 20(6):1472-1481. PubMed ID: 37306928
[TBL] [Abstract][Full Text] [Related]
30. Glibenclamide for the treatment of ischemic and hemorrhagic stroke.
Caffes N; Kurland DB; Gerzanich V; Simard JM
Int J Mol Sci; 2015 Mar; 16(3):4973-84. PubMed ID: 25749474
[TBL] [Abstract][Full Text] [Related]
31. Indomethacin in the management of elevated intracranial pressure: a review.
Harrigan MR; Tuteja S; Neudeck BL
J Neurotrauma; 1997 Sep; 14(9):637-50. PubMed ID: 9337126
[TBL] [Abstract][Full Text] [Related]
32. Found in translation: The rationale behind the early development of glibenclamide in large hemispheric infarction.
Jacobson SM; MacAllister TW; Geliebter DM
Neurosci Lett; 2020 Jan; 716():134672. PubMed ID: 31805373
[TBL] [Abstract][Full Text] [Related]
33. BIIB093 (intravenous glibenclamide) for the prevention of severe cerebral edema.
Griepp DW; Lee J; Moawad CM; Davati C; Runnels J; Fiani B
Surg Neurol Int; 2021; 12():80. PubMed ID: 33767884
[TBL] [Abstract][Full Text] [Related]
34. A Comparison of Pharmacologic Therapeutic Agents Used for the Reduction of Intracranial Pressure After Traumatic Brain Injury.
Alnemari AM; Krafcik BM; Mansour TR; Gaudin D
World Neurosurg; 2017 Oct; 106():509-528. PubMed ID: 28712906
[TBL] [Abstract][Full Text] [Related]
35. Emerging therapeutic targets for cerebral edema.
Jha RM; Raikwar SP; Mihaljevic S; Casabella AM; Catapano JS; Rani A; Desai S; Gerzanich V; Simard JM
Expert Opin Ther Targets; 2021 Nov; 25(11):917-938. PubMed ID: 34844502
[TBL] [Abstract][Full Text] [Related]
36. [Current status of treatment of the cerebral edema].
Richling B
Anaesthesist; 1987 May; 36(5):191-6. PubMed ID: 3115135
[TBL] [Abstract][Full Text] [Related]
37. Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies.
Stokum JA; Gerzanich V; Sheth KN; Kimberly WT; Simard JM
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():291-309. PubMed ID: 31914899
[TBL] [Abstract][Full Text] [Related]
38. [Modern oral sugar-reducing drugs: focus to glibenclamide].
Ushakova EA
Ter Arkh; 2007; 79(12):86-90. PubMed ID: 18220041
[No Abstract] [Full Text] [Related]
39. Sulfonylurea and neuroprotection: The bright side of the moon.
Hussien NR; Al-Naimi MS; Rasheed HA; Al-Kuraishy HM; Al-Gareeb AI
J Adv Pharm Technol Res; 2018; 9(4):120-123. PubMed ID: 30637228
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
